실시간
FierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Lonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesEndpoints NewsParabilis Medicines charts $413M IPO to back peptide pipelineFierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’BioWorldFDA clears Shionogi’s Xocova as first COVID-19 prevention pillBrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.comBrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報
FierceBiotech 2026년 4월 20일

How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients

How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.